You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Mycotoxin Neutralization Treatment
SBC: Physical Optics Corporation Topic: CBD152003To address the Chemical and Biological Defense programs (CBDs) need for medical countermeasures against mycotoxin intoxication, PhysicalOptics Corporation (POC) proposes to develop a new Mycotoxin Neutralization Treatment (MyNT). This proposed solution is based on neutralizingmycotoxin from its deleterious effects by acting on multiple levels of mycotoxin metabolism through the novel combination o ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Human monoclonal antibodies as countermeasures for T-2 mycotoxin
SBC: ABZYME THERAPEUTICS LLC Topic: CBD152003Mycotoxins are fungal toxins to which exposure frequently results in incapacitation or even in death. Natural outbreaks of mycotoxin poisoningare common worldwide. Due to its physical-chemical properties, high toxicity and relative ease to produce, mycotoxin T-2 is classified as apotential biological warfare agent. Currently there are no FDA approved medical countermeasures available for T-2 mycot ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Mycotoxin Adsorption with Hemocompatible Porous Polymer Beads
SBC: CYTOSORBENTS MEDICAL INC Topic: CBD152003Acute exposure to mycotoxins can lead to systemic toxicity and even death. With no specific treatment available, aflatoxin and trichothecene T-2toxin, in particular, are of concern as potential biological weapons due to their toxicity, thermal and UV stability and easy accessibility. As amedical countermeasure, we propose the development of highly porous polymer beads optimized for removal of afla ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation
SBC: CFD RESEARCH CORPORATION Topic: CBD152003Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Adjustable Focus Lenses for Respiratory Protection
SBC: VOXTEL, INC. Topic: CBD152001A low-cost, adjustable optical-correction technology will be developed for integration with AVON M50 respiratory protective masks, allowing forfast, adjustable vision correction. Variable-focus lenses will be designed using 3D freeform gradient index materials, which allow both opticalpower and geometric and chromatic aberrations corrections to be achieved in planar films. A Phase I prototype will ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Novel Smart Split Neck Seals for Respiratory Protection
SBC: TRITON SYSTEMS, INC. Topic: CBD152002This development is to address the current limitation in respiratory protection neck seal designs. The developed system will allow for a smart splitneck seal design that allows for donning versatility, improved comfort, and will provide feedback to the user regarding seal performance. Theapplication of smart technology will help balance comfort with protection in ensuring that a hermetic neck seal ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Exploiting Microbiome and Synthetic Biology to Discover and Produce Naturally Occurring Antibiotics
SBC: Radiant Genomics, Inc. Topic: CBD152004In this proposal, we aim to validate the human gut microbiome and arid soil as a source of antibiotic natural products (NPs ) by using ametagenomic NP discovery platform developed at Radiant Genomics. Recent studies suggest that the genomes of uncultivated microorganisms,like their cultivated counterparts, encode an enormous number of NPs. Gaining systematic access to NPs using standard, cultivati ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Producing Novel Biosynthetic Therapeutics from Extreme Microbiomes
SBC: iXpressGenes, Inc. Topic: CBD152004Environmental DNA from three extreme samples will be isolated, cloned into a fosmid library (5760 clones) for sequencing. The sequencing datawill cover ~ 240 Megabases and will be assembled into contigs long enough (~ 40 Kilobases) to represent potential biosynthetic gene clusters(BGCs). This data will be compared to BGC databases looking for homology to antibiotic targets of DoD interest and with ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
High Sensitivity, Low Complexity, Multiplexed Diagnostic Devices
SBC: Paratus Diagnostics Topic: CBD152005Infectious diseases have been a constant cause of non-battlefield injury and illness for military personnel engaged in operations throughout theworld. Detection of these infectious pathogens is critical to proper patient care and management of outbreaks, yet many existing diagnostic testsfail to provide adequate sensitivity and/or simplicity for use in forward locations or in isolated areas. We pr ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Innovative concept for detection and identification of biological toxins
SBC: DAKTARI DIAGNOSTICS, INC. Topic: CBD152005The focus of this SBIR proposal is to demonstrate rapid, multiplexed detection of acute bacterial and viral pathogens of global importance on asingle test platform. Daktaris microfluidic immunoassay platform, under development since 2009 for HIV and hepatitis C (HCV) applications, iscapable of femtomolar detection of bacterial and viral antigens consistent with needs for infectious disease diagnos ...
SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense